Behfar Atta, Terzic Andre, Perez-Terzic Carmen M
From the Division of Cardiovascular Diseases, Department of Medicine (AB, AT, CMP-T), Department of Molecular Pharmacology and Experimental Therapeutics (AT), Department of Physical Medicine and Rehabilitation (CMP-T), and Center for Regenerative Medicine (AB, AT), Mayo Clinic, Rochester, Minnesota.
Am J Phys Med Rehabil. 2014 Nov;93(11 Suppl 3):S169-75. doi: 10.1097/PHM.0000000000000147.
Cardiovascular morbidity imposes a high degree of disability and mortality, with limited therapeutic options available in end-stage disease. Integral to standard of care, cardiac rehabilitation aims on improving quality-of-life and prolonging survival. The recent advent of regenerative technologies paves the way for a transformative era in rehabilitation medicine whereby, beyond controlling risk factors and disease progression, the prospect of curative solutions is increasingly tangible. To date, the spectrum of clinical experience in cardiac regenerative medicine relies on stem cell-based therapies delivered to the diseased myocardium either acutely/subacutely, after a coronary event, or in the setting of chronic heart failure. Application of autologous/allogeneic stem cell platforms has established safety and feasibility, with encouraging signals of efficacy. Newer protocols aim to purify cell populations in an attempt to eliminate nonregenerative and enrich for regenerative cell types before use. Most advanced technologies have been developed to isolate resident cell populations directly from the heart or, alternatively, condition cells from noncardiac sources to attain a disease-targeted lineage-specified phenotype for optimized outcome. Because a multiplicity of cell-based technologies has undergone phase I/II evaluation, pivotal trials are currently underway in larger patient populations. Translation of regenerative principles into clinical practice will increasingly involve rehabilitation providers across the continuum of patient care. Regenerative rehabilitation is thus an emerging multidisciplinary field, full of opportunities and ready to be explored.
心血管疾病的发病率导致了高度的残疾和死亡率,而在疾病终末期可供选择的治疗方法有限。心脏康复作为标准治疗的一部分,旨在提高生活质量和延长生存期。再生技术的最新出现为康复医学的变革时代铺平了道路,在这个时代,除了控制危险因素和疾病进展外,治愈性解决方案的前景越来越切实可行。迄今为止,心脏再生医学的临床经验范围依赖于在急性/亚急性阶段、冠状动脉事件后或慢性心力衰竭情况下,将基于干细胞的疗法应用于患病心肌。自体/异体干细胞平台的应用已确立了安全性和可行性,并出现了令人鼓舞的疗效信号。更新的方案旨在纯化细胞群体,以便在使用前消除非再生细胞并富集再生细胞类型。大多数先进技术已被开发出来,用于直接从心脏中分离驻留细胞群体,或者对非心脏来源的细胞进行处理,以获得针对疾病的谱系特异性表型,从而实现优化结果。由于多种基于细胞的技术已经进行了I/II期评估,目前正在更大规模的患者群体中进行关键试验。将再生原理转化为临床实践将越来越多地涉及患者护理全过程中的康复提供者。因此,再生康复是一个新兴的多学科领域,充满机遇,有待探索。